Phaseline

Targets › COL3

COL3: drug programs, companies and trials

2 programs from 1 company in 2 trials: 2 Phase 1; Other; next expected readout May 2029.

Open in Phaseline: the race on COL3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Krystal BiotechKB301
Replication-incompetent, non-integrating HSV-1 vector expressing human type III collagen
COL3Phase 1Skin RoughnessMay 2029
Krystal BiotechKB304
HSV-1 vector delivering human collagen (COL3) and elastin (tropoelastin) genes
COL3, ELNPhase 1Wrinkles in Decolletage–

Conditions

Skin Roughness (1) Wrinkles in Decolletage (1)

Modalities

protein or peptide (2)

Companies

Krystal Biotech (2)

Related targets

ELN (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.